BW 00112
Alternative Names: BW-00112Latest Information Update: 29 Jul 2024
At a glance
- Originator Argo Biopharma
- Class Antihyperlipidaemics; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Dyslipidaemias
Most Recent Events
- 12 Jul 2024 Argo Biopharmaceutical plans a phase II trial for Dyslipidemias (SC) in July 2024 (NCT06497127) (Argo Biopharmaceutical website, July 2024)
- 14 Nov 2023 Argo Biopharma completes a phase-I clinical trials in Dyslipidaemias in Australia (SC) (ACTRN12622001429741)
- 31 Dec 2022 Preclinical trials in Dyslipidaemias in China (SC) before December 2022 (Argo Biopharmaceutical website, July 2024)